27
Participants
Start Date
January 21, 2016
Primary Completion Date
June 12, 2018
Study Completion Date
December 31, 2022
Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
Dose-escalation trial starting dose: 0.66x10\^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0
Cyclophosphamide
300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
Fludarabine
30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Cancer Institute (NCI)
NIH